| Â | KRT | MV | VD |
|---|
OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P |
|---|
Unmatched cohort | Unadjusted | 1.09 (0.96–1.24) | 0.16 | 1.30 (1.22–1.40) |  < 0.001 | 1.16 (1.08–1.24) | 0.006 |
Adjusted | – | – | 1.15 (1.04–1.29) |  < 0.001 | 1.10 (1.01–1.20) | 0.03 |
Matched cohort | Unadjusted | 0.95 (0.82–1.10) | 0.52 | 0.96 (0.89–1.04) | 0.35 | 0.97 (0.89–1.05) | 0.40 |
Adjusted | – | – | 0.95 (0.86–1.04) | 0.27 | 1.10 (0.99–1.22) | 0.53 |
- SA-AKI sepsis associated acute kidney injury, KRT Kidney Replacement Therapy, MV Mechanical Ventilation, VD Vasopressor Drug
- Adjusted variations: age, race, BMI, admission type, infection resources, microorganisms, hypertension, coronary atherosclerosis, chronic heart failure, chronic liver disease, diabetes, chronic kidney disease, peripheral vascular disease,chronic pulmonary disease, cancer, KRT, Mechnical ventilation, Vasopressor use, Diuretic, Statin, ACEI/ARBs, Contrast, Vancomycin, Aminoglycosides, apsiii, sofa, oasis, sapsII, BUN, Creatinine, Potassium, Chloride, PT, Hemoglobin, Lactate, NLR, Proteinuria, Pao2/Fio2, PO2, Bicarbonate, MAP, Temperature
